

Michael A Jakupec

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1410878/publications.pdf>

Version: 2024-02-01

189
papers

12,709
citations

24978

57
h-index

27345

106
g-index

196
all docs

196
docs citations

196
times ranked

8581
citing authors

#	ARTICLE	IF	CITATIONS
1	From bench to bedside â€“ preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 891-904.	1.5	882
2	Antitumour metal compounds: more than theme and variations. <i>Dalton Transactions</i> , 2007, , 183-194.	1.6	767
3	KP1019, A New Redoxâ€Active Anticancer Agent â€“ Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. <i>Chemistry and Biodiversity</i> , 2008, 5, 2140-2155.	1.0	732
4	Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches. <i>Current Medicinal Chemistry</i> , 2005, 12, 2075-2094.	1.2	657
5	NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. <i>Chemical Science</i> , 2014, 5, 2925-2932.	3.7	552
6	Structureâ€Activity Relationships for NAMI-A-type Complexes (HL)[trans-RuCl ₄ L(S-dmso)ruthenate(III)] (L = Imidazole, Indazole, 1,2,4-Triazole, 4-Amino-1,2,4-triazole, and 1-Methyl-1,2,4-triazole): Aqueous Solution, Redox Properties, Protein Binding, and Antiproliferative Activity. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 2185-2193.	2.9	206
7	Resistance against novel anticancer metal compounds: Differences and similarities. <i>Drug Resistance Updates</i> , 2008, 11, 1-16.	6.5	201
8	Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. <i>Dalton Transactions</i> , 2006, , 1796.	1.6	197
9	Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. <i>Journal of Analytical Atomic Spectrometry</i> , 2004, 19, 46.	1.6	183
10	Influence of the Spacer Length on the <i>In Vitro</i> Anticancer Activity of Dinuclear Rutheniumâ€Arene Compounds. <i>Organometallics</i> , 2008, 27, 2405-2407.	1.1	180
11	Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer Activity. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 916-925.	2.9	168
12	Redox-Active Antineoplastic Ruthenium Complexes with Indazole: A Correlation of <i>In Vitro</i> Potency and Reduction Potential. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2831-2837.	2.9	156
13	Gallium(III) and Iron(III) Complexes of β -N-Heterocyclic Thiosemicarbazones: Synthesis, Characterization, Cytotoxicity, and Interaction with Ribonucleotide Reductase. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1254-1265.	2.9	145
14	Impact of Metal Coordination on Cytotoxicity of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (Triapine) and Novel Insights into Terminal Dimethylation. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5032-5043.	2.9	143
15	Gallium in Cancer Treatment. <i>Current Topics in Medicinal Chemistry</i> , 2004, 4, 1575-1583.	1.0	138
16	Highly Antiproliferative Ruthenium(II) and Osmium(II) Arene Complexes with Paullone-Derived Ligands. <i>Organometallics</i> , 2007, 26, 6643-6652.	1.1	134
17	Structureâ€Activity Relationships of Targeted Ru ^{II} (η^6 -p-Cymene) Anticancer Complexes with Flavonol-Derived Ligands. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10512-10522.	2.9	132
18	Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder. <i>Chemical Communications</i> , 2012, 48, 4839.	2.2	130

#	ARTICLE	IF	CITATIONS
19	Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. <i>Chemical Communications</i> , 2013, 49, 3348.	2.2	127
20	Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action. <i>Chemical Science</i> , 2015, 6, 2449-2456.	3.7	127
21	Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). <i>Biochemical Pharmacology</i> , 2006, 71, 426-440.	2.0	124
22	The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. <i>Cancer Letters</i> , 2005, 226, 115-121.	3.2	111
23	In Vitro Anticancer Activity and Biologically Relevant Metabolization of Organometallic Ruthenium Complexes with Carbohydrate-Based Ligands. <i>Chemistry - A European Journal</i> , 2008, 14, 9046-9057.	1.7	111
24	Maltol-Derived Ruthenium-Cymene Complexes with Tumor Inhibiting Properties: The Impact of Ligand-Metal Bond Stability on Anticancer Activity In Vitro. <i>Chemistry - A European Journal</i> , 2009, 15, 12283-12291.	1.7	111
25	Novel metal(ii) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents. <i>Chemical Science</i> , 2013, 4, 1837.	3.7	111
26	Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 46-51.	1.5	107
27	Physicochemical Studies and Anticancer Potency of Ruthenium(II)-Cymene Complexes Containing Antibacterial Quinolones. <i>Organometallics</i> , 2011, 30, 2506-2512.	1.1	105
28	Is the Reactivity of M(II)-Arene Complexes of 3-Hydroxy-2-pyridones to Biomolecules the Anticancer Activity Determining Parameter?. <i>Inorganic Chemistry</i> , 2010, 49, 7953-7963.	1.9	101
29	Preclinical characterization of anticancer gallium(III) complexes: Solubility, stability, lipophilicity and binding to serum proteins. <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 1819-1826.	1.5	100
30	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. <i>Journal of Analytical Atomic Spectrometry</i> , 2009, 24, 51-61.	1.6	100
31	A SAR Study of Novel Antiproliferative Ruthenium and Osmium Complexes with Quinoxalinone Ligands in Human Cancer Cell Lines. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3398-3413.	2.9	98
32	Synthesis, structure, spectroscopic and in vitro antitumor studies of a novel gallium(III) complex with 2-acetylpyridine 4N-dimethylthiosemicarbazone. <i>Journal of Inorganic Biochemistry</i> , 2002, 91, 298-305.	1.5	97
33	An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 8267-8271.	7.2	97
34	Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines. <i>Investigational New Drugs</i> , 2016, 34, 261-268.	1.2	96
35	Synthesis, X-ray Diffraction Structures, Spectroscopic Properties, and in vitro Antitumor Activity of Isomeric (1H-1,2,4-Triazole)Ru(III) Complexes. <i>Inorganic Chemistry</i> , 2003, 42, 6024-6031.	1.9	94
36	Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on the In Vitro Antitumor Activity of Polynuclear Organometallic Compounds. <i>Organometallics</i> , 2009, 28, 6260-6265.	1.1	92

#	ARTICLE	IF	CITATIONS
37	First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids <i>in vitro</i> . <i>Metallomics</i> , 2019, 11, 1044-1048.	1.0	92
38	Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules. <i>Chemical Communications</i> , 2012, 48, 1475-1477.	2.2	91
39	Novel Di- and Tetracarboxylatoplatinum(IV) Complexes. Synthesis, Characterization, Cytotoxic Activity, and DNA Platination. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 6692-6699.	2.9	88
40	Osmium(ii) versus ruthenium(ii) arene carbohydrate-based anticancer compounds: similarities and differences. <i>Dalton Transactions</i> , 2010, 39, 7345.	1.6	88
41	NanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugs. <i>Chemical Science</i> , 2014, 5, 3135-3143.	3.7	87
42	Metal-Based Paullones as Putative CDK Inhibitors for Antitumor Chemotherapy. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 6343-6355.	2.9	86
43	From Pyrone to Thiopyrone Ligands Rendering Maltol-Derived Ruthenium(II) Arene Complexes That Are Anticancer Active <i>In Vitro</i> . <i>Organometallics</i> , 2009, 28, 4249-4251.	1.1	85
44	Fluorescence properties and cellular distribution of the investigational anticancer drug Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(ii) complex. <i>Dalton Transactions</i> , 2010, 39, 704-706.	1.6	77
45	Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs. <i>Dalton Transactions</i> , 2012, 41, 14404-14415.	1.6	76
46	Theoretical Investigations and Density Functional Theory Based Quantitative Structure-Activity Relationships Model for Novel Cytotoxic Platinum(IV) Complexes. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 330-344.	2.9	76
47	3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II) (arene) anticancer complexes with biologically active ligands. <i>Dalton Transactions</i> , 2013, 42, 6193-6202.	1.6	74
48	Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: Synthesis, solution speciation and bioactivity. <i>Journal of Inorganic Biochemistry</i> , 2014, 134, 57-65.	1.5	73
49	Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones. <i>Journal of Inorganic Biochemistry</i> , 2007, 101, 1946-1957.	1.5	71
50	Water-Soluble Mixed-Ligand Ruthenium(II) and Osmium(II) Arene Complexes with High Antiproliferative Activity. <i>Organometallics</i> , 2008, 27, 6587-6595.	1.1	71
51	Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 5456-5464.	2.6	70
52	Osmium NAMI-A Analogues: Synthesis, Structural and Spectroscopic Characterization, and Antiproliferative Properties. <i>Inorganic Chemistry</i> , 2007, 46, 5023-5033.	1.9	66
53	From hydrolytically labile to hydrolytically stable Ru(II) arene anticancer complexes with carbohydrate-derived co-ligands. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 224-231.	1.5	65
54	Solid-phase synthesis of oxaliplatin-TAT peptide bioconjugates. <i>Dalton Transactions</i> , 2012, 41, 3001-3005.	1.6	65

#	ARTICLE	IF	CITATIONS
55	Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety. <i>Journal of Organometallic Chemistry</i> , 2009, 694, 922-929.	0.8	64
56	l- and d-Proline Thiosemicarbazone Conjugates: Coordination Behavior in Solution and the Effect of Copper(II) Coordination on Their Antiproliferative Activity. <i>Inorganic Chemistry</i> , 2012, 51, 9309-9321.	1.9	64
57	Comparative studies of oxaliplatin-based platinum(IV) complexes in different in vitro and in vivo tumor models. <i>Metallomics</i> , 2017, 9, 309-322.	1.0	60
58	Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2012, 116, 180-187.	1.5	59
59	Synthesis, Characterization, and in Vitro Antitumor Activity of Osteotropic Diam(m)ineplatinum(II) Complexes Bearing aN,N-Bis(phosphonomethyl)glycine Ligand. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 4946-4951.	2.9	58
60	Identification of the Structural Determinants for Anticancer Activity of a Ruthenium Arene Peptide Conjugate. <i>Chemistry - A European Journal</i> , 2013, 19, 9297-9307.	1.7	58
61	Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation. <i>Organometallics</i> , 2013, 32, 903-914.	1.1	57
62	Synthesis and biological studies of some gold(I) complexes containing functionalised alkynes. <i>Dalton Transactions</i> , 2009, , 10841.	1.6	56
63	The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines. <i>Melanoma Research</i> , 2009, 19, 283-293.	0.6	56
64	Conjugation of Organoruthenium(II) 3-(1H-Benzimidazol-2-yl)pyrazolo[3,4-b]pyridines and Indolo[3,2-d]benzazepines to Recombinant Human Serum Albumin: a Strategy To Enhance Cytotoxicity in Cancer Cells. <i>Inorganic Chemistry</i> , 2011, 50, 12669-12679.	1.9	56
65	Structure-Activity Relationships of Highly Cytotoxic Copper(II) Complexes with Modified Indolo[3,2-c]quinoline Ligands. <i>Inorganic Chemistry</i> , 2010, 49, 11084-11095.	1.9	55
66	Ruthenium and Osmium-Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity. <i>Organometallics</i> , 2011, 30, 273-283.	1.1	55
67	Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs. <i>Molecular Pharmacology</i> , 2012, 81, 719-728.	1.0	54
68	Reversion of Structure-Activity Relationships of Antitumor Platinum Complexes by Acetoxime but Not Hydroxylamine Ligands. <i>Molecular Pharmacology</i> , 2007, 71, 357-365.	1.0	53
69	Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates. <i>Inorganic Chemistry</i> , 2017, 56, 528-541.	1.9	52
70	Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible. <i>European Journal of Medicinal Chemistry</i> , 2004, 39, 707-714.	2.6	51
71	Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. <i>Journal of Biological Inorganic Chemistry</i> , 2010, 15, 903-918.	1.1	51
72	{(1 <i>R</i> ,2 <i>R</i> ,4 <i>R</i>)-4-Methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): A Novel Enantiomerically Pure Oxaliplatin Derivative Showing Improved Anticancer Activity in Vivo. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7356-7364.	2.9	51

#	ARTICLE	IF	CITATIONS
73	Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. <i>Journal of Biological Inorganic Chemistry</i> , 2012, 17, 465-474.	1.1	51
74	New platinum-oxo complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. <i>Journal of Inorganic Biochemistry</i> , 2010, 104, 799-814.	1.5	50
75	A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?. <i>ChemMedChem</i> , 2007, 2, 505-514.	1.6	49
76	Novel Cis- and Trans-Configured Bis(oxime)platinum(II) Complexes: Synthesis, Characterization, and Cytotoxic Activity. <i>Inorganic Chemistry</i> , 2010, 49, 5669-5678.	1.9	49
77	En Route to Osmium Analogues of KP1019: Synthesis, Structure, Spectroscopic Properties and Antiproliferative Activity of <i>trans</i> -[Os ^{IV} Cl ₄ (Hazole) ₂]. <i>Inorganic Chemistry</i> , 2011, 50, 7690-7697.	1.9	49
78	X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium <i>trans</i> -[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1182-1196.	2.9	49
79	A Novel Class of Bis- and Tris-Chelate Diam(m)inebis(dicarboxylato)platinum(IV) Complexes as Potential Anticancer Prodrugs. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6751-6764.	2.9	49
80	Highly Cytotoxic Copper(II) Complexes with Modified Paullone Ligands. <i>Inorganic Chemistry</i> , 2010, 49, 302-311.	1.9	48
81	Synthesis, crystal structure and pH dependent cytotoxicity of (SP-4-2)-bis(2-aminoethanolato- η^2 N,O)platinum(II) – a representative of novel pH sensitive anticancer platinum complexes. <i>Inorganica Chimica Acta</i> , 2004, 357, 3237-3244.	1.2	46
82	The First Metal-Based Paullone Derivative with High Antiproliferative Activity in Vitro. <i>Inorganic Chemistry</i> , 2006, 45, 1945-1950.	1.9	46
83	Towards targeting anticancer drugs: ruthenium(II)-arene complexes with biologically active naphthoquinone-derived ligand systems. <i>Dalton Transactions</i> , 2016, 45, 13091-13103.	1.6	45
84	Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action. <i>Inorganic Chemistry</i> , 2018, 57, 2851-2864.	1.9	45
85	Gallium and Other Main Group Metal Compounds as Antitumor Agents. , 2004, , 425-462.		45
86	Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs. <i>Investigational New Drugs</i> , 2015, 33, 835-847.	1.2	44
87	Ruthenium(II) Complexes of Thiosemicarbazones: The First Water-Soluble Complex with pH-Dependent Antiproliferative Activity. <i>European Journal of Inorganic Chemistry</i> , 2007, 2007, 2870-2878.	1.0	43
88	Novel bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) complexes with exceptionally high cytotoxicity. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 2072-2077.	1.5	41
89	The First Ruthenium-Based Paullones: Syntheses, X-ray Diffraction Structures, and Spectroscopic and Antiproliferative Properties in Vitro. <i>Inorganic Chemistry</i> , 2007, 46, 3645-3656.	1.9	40
90	Ruthenium- and osmium-arene-based paullones bearing a TEMPO free-radical unit as potential anticancer drugs. <i>Chemical Communications</i> , 2012, 48, 8559.	2.2	40

#	ARTICLE	IF	CITATIONS
91	The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 264-274.	1.5	40
92	Striking Difference in Antiproliferative Activity of Ruthenium- and Osmium-Nitrosyl Complexes with Azole Heterocycles. <i>Inorganic Chemistry</i> , 2013, 52, 6273-6285.	1.9	39
93	Behavior of platinum(IV) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. <i>Metallomics</i> , 2016, 8, 422-433.	1.0	39
94	Novel Endothelium-Containing Platinum(IV) Complexes: Synthesis, Characterization, and Cytotoxic Activity. <i>Chemistry and Biodiversity</i> , 2008, 5, 2160-2170.	1.0	38
95	Osmium(IV) complexes with 1H- and 2H-indazoles: Tautomer identity versus spectroscopic properties and antiproliferative activity. <i>Journal of Inorganic Biochemistry</i> , 2012, 113, 47-54.	1.5	38
96	LA-ICP-MS imaging in multicellular tumor spheroids – a novel tool in the preclinical development of metal-based anticancer drugs. <i>Metallomics</i> , 2016, 8, 398-402.	1.0	38
97	X-ray Absorption Spectroscopy of an Investigational Anticancer Gallium(III) Drug: Interaction with Serum Proteins, Elemental Distribution Pattern, and Coordination of the Compound in Tissue. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5601-5613.	2.9	36
98	Triapine and a More Potent Dimethyl Derivative Induce Endoplasmic Reticulum Stress in Cancer Cells. <i>Molecular Pharmacology</i> , 2014, 85, 451-459.	1.0	35
99	Ruthenium-Nitrosyl Complexes with Glycine, L-Alanine, L-Valine, L-Proline, D-Proline, L-Serine, L-Threonine, and L-Tyrosine: Synthesis, X-ray Diffraction Structures, Spectroscopic and Electrochemical Properties, and Antiproliferative Activity. <i>Inorganic Chemistry</i> , 2014, 53, 2718-2729.	1.9	35
100	Synthesis, Characterization, and Cytotoxic Activity of Novel Potentially pH-Sensitive Nonclassical Platinum(II) Complexes Featuring 1,3-Dihydroxyacetone Oxime Ligands. <i>Inorganic Chemistry</i> , 2011, 50, 10673-10681.	1.9	34
101	Unsymmetric Mono- and Dinuclear Platinum(IV) Complexes Featuring an Ethylene Glycol Moiety: Synthesis, Characterization, and Biological Activity. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 11052-11061.	2.9	34
102	Influence of reducing agents on the cytotoxic activity of platinum(IV) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin resistant A2780cis cell lines. <i>Metallomics</i> , 2015, 7, 1078-1090.	1.0	34
103	Influence of the Arene Ligand and the Leaving Group on the Anticancer Activity of (Thio)maltol Ruthenium(II) (6-Arene) Complexes. <i>Australian Journal of Chemistry</i> , 2010, 63, 1521.	0.5	33
104	Mono-carboxylated diaminedichloridoplatinum(IV) complexes – selective synthesis, characterization, and cytotoxicity. <i>Dalton Transactions</i> , 2011, 40, 8187-8192.	1.6	33
105	Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity In Vitro of Novel Osmium(III) Complexes with Azole Heterocycles. <i>Inorganic Chemistry</i> , 2008, 47, 7338-7347.	1.9	32
106	Organometallic 3-(1H-Benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as Potential Anticancer Agents. <i>Inorganic Chemistry</i> , 2011, 50, 11715-11728.	1.9	32
107	Bulky N,N'-((Di)alkylethane-1,2-diamine)platinum(II) Compounds as Precursors for Generating Unsymmetrically Substituted Platinum(IV) Complexes. <i>Inorganic Chemistry</i> , 2013, 52, 8151-8162.	1.9	32
108	Guanidine platinum(II) complexes: synthesis, in vitro antitumor activity, and DNA interactions. <i>Journal of Inorganic Biochemistry</i> , 2014, 133, 33-39.	1.5	32

#	ARTICLE	IF	CITATIONS
109	Thiomaltolâ€Based Organometallic Complexes with 1â€Methylimidazole as Leaving Group: Synthesis, Stability, and Biological Behavior. <i>Chemistry - A European Journal</i> , 2016, 22, 17269-17281.	1.7	32
110	Synthesis and in vivo anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates. <i>Dalton Transactions</i> , 2017, 46, 12114-12124.	1.6	32
111	Am(m)ines Make the Difference: Organoruthenium Am(m)ine Complexes and Their Chemistry in Anticancer Drug Development. <i>Chemistry - A European Journal</i> , 2013, 19, 4308-4318.	1.7	31
112	Synthesis, structures and in vitro cytotoxicity of some platinum(II) complexes containing thiocarbamate esters. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 2067-2071.	1.5	29
113	Novel glucose-ferrocenyl derivatives: synthesis and properties. <i>New Journal of Chemistry</i> , 2002, 26, 671-673.	1.4	28
114	Platinum(IV) Complexes Featuring One or Two Axial Ferrocene Bearing Ligands â€“ Synthesis, Characterization, and Cytotoxicity. <i>European Journal of Inorganic Chemistry</i> , 2014, 2014, 484-492.	1.0	28
115	Synthesis, X-ray diffraction structure, spectroscopic properties and antiproliferative activity of a novel ruthenium complex with constitutional similarity to cisplatin. <i>Dalton Transactions</i> , 2009, , 3334.	1.6	27
116	{Ru(CO) _x }-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivo. <i>Dalton Transactions</i> , 2017, 46, 3025-3040.	1.6	27
117	Plecstatin-1 induces an immunogenic cell death signature in colorectal tumour spheroids. <i>Metallomics</i> , 2020, 12, 2121-2133.	1.0	27
118	1,3-Dioxoindan-2-carboxamides as Bioactive Ligand Scaffolds for the Development of Novel Organometallic Anticancer Drugs. <i>Organometallics</i> , 2015, 34, 848-857.	1.1	25
119	Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles. <i>Journal of Biological Inorganic Chemistry</i> , 2016, 21, 347-356.	1.1	25
120	Impact of the equatorial coordination sphere on the rate of reduction, lipophilicity and cytotoxic activity of platinum(IV) complexes. <i>Journal of Inorganic Biochemistry</i> , 2017, 174, 119-129.	1.5	25
121	{Ru(CO) _x }-core complexes with selected azoles: Synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells. <i>Polyhedron</i> , 2014, 81, 227-237.	1.0	24
122	Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups â€” A rational approach toward exploiting the platinum(IV) prodrug strategy. <i>Journal of Inorganic Biochemistry</i> , 2015, 153, 259-271.	1.5	24
123	Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019. <i>Journal of Biological Inorganic Chemistry</i> , 2011, 16, 1205-1215.	1.1	23
124	Influence of the Î€-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes. <i>Frontiers in Chemistry</i> , 2013, 1, 27.	1.8	23
125	Novel Oximato-Bridged Platinum(II) Di- and Trimer(s): Synthetic, Structural, and in Vitro Anticancer Activity Studies. <i>Inorganic Chemistry</i> , 2012, 51, 7153-7163.	1.9	22
126	Dicopper(II) and Dizinc(II) Complexes with Nonsymmetric Dinucleating Ligands Based on Indolo[3,2- <i>c</i>]quinolines: Synthesis, Structure, Cytotoxicity, and Intracellular Distribution. <i>Inorganic Chemistry</i> , 2013, 52, 10137-10146.	1.9	22

#	ARTICLE	IF	CITATIONS
127	Solution equilibria and antitumor activities of pentamethylcyclopentadienyl rhodium complexes of picolinic acid and deferiprone. <i>Journal of Coordination Chemistry</i> , 2015, 68, 1583-1601.	0.8	22
128	A Novel Cytotoxic Cerium Complex: Aquatrchloridobis(1,10-phenanthroline)cerium(III) (KP776). Synthesis, Characterization, Behavior in H ₂ O, Binding towards Biomolecules, and Antiproliferative Activity. <i>Chemistry and Biodiversity</i> , 2009, 6, 2153-2165.	1.0	21
129	[Os ^{IV} Cl ₅ (Hazole)] ⁺ Complexes: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity. <i>Inorganic Chemistry</i> , 2009, 48, 10737-10747.	1.9	21
130	Flavonoid-Based Organometallics with Different Metal Centers – Investigations of the Effects on Reactivity and Cytotoxicity. <i>European Journal of Inorganic Chemistry</i> , 2016, 2016, 240-246.	1.0	21
131	Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics. <i>Metallomics</i> , 2019, 11, 1716-1728.	1.0	21
132	Ruthenium- and osmium-arene complexes of 8-substituted indolo[3,2-c]quinolines: Synthesis, X-ray diffraction structures, spectroscopic properties, and antiproliferative activity. <i>Inorganica Chimica Acta</i> , 2012, 393, 252-260.	1.2	20
133	Cytotoxicity and preliminary mode of action studies of novel 2-aryl-4-thiopyrone-based organometallics. <i>Dalton Transactions</i> , 2016, 45, 724-733.	1.6	20
134	Low-Generation Polyamidoamine Dendrimers as Drug Carriers for Platinum(IV) Complexes. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1713-1720.	1.0	20
135	A highly cytotoxic modified paullone ligand bearing a TEMPO free-radical unit and its copper(ii) complex as potential hR2 RNR inhibitors. <i>Chemical Communications</i> , 2013, 49, 10007.	2.2	18
136	N- and S-donor leaving groups in triazole-based ruthena(ⁱⁱ)cycles: potent anticancer activity, selective activation, and mode of action studies. <i>Dalton Transactions</i> , 2018, 47, 4625-4638.	1.6	18
137	Post-digestion stabilization of osmium enables quantification by ICP-MS in cell culture and tissue. <i>Analyst</i> , 2017, 142, 2327-2332.	1.7	17
138	Synthesis, Cytotoxicity, and Structure-Activity Relationships of New Oxaliplatin Derivatives. <i>Monatshefte für Chemie</i> , 2005, 136, 693-700.	0.9	16
139	Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes. <i>Journal of Biological Inorganic Chemistry</i> , 2013, 18, 249-260.	1.1	16
140	Single Spheroid Metabolomics: Optimizing Sample Preparation of Three-Dimensional Multicellular Tumor Spheroids. <i>Metabolites</i> , 2019, 9, 304.	1.3	16
141	Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase II± inhibitors. <i>Journal of Biological Inorganic Chemistry</i> , 2020, 25, 451-465.	1.1	16
142	Expanding on the Structural Diversity of Flavone-Derived Ruthenium(III)-arene Anticancer Agents. <i>Metallodrugs</i> , 2015, 1, .	1.7	15
143	Complexes of N-hydroxyethyl-N-benzimidazolylmethylethylenediaminediacetic acid with group 12 metals and vanadium – Synthesis, structure and bioactivity of the vanadium complex. <i>Journal of Inorganic Biochemistry</i> , 2015, 147, 147-152.	1.5	15
144	Organometallic complexes of (thio)allomaltol-based Mannich-products: Synthesis, stability and preliminary biological investigations. <i>Journal of Organometallic Chemistry</i> , 2015, 782, 69-76.	0.8	15

#	ARTICLE	IF	CITATIONS
145	Tetra-(<i>p</i> -tolyl)antimony(III)-Containing Heteropolytungstates, $[(p\text{-tolyl})\text{Sb}^{\text{III}}]_4\text{XW}_9\text{O}_{34}$ (X = P, As, or Ge): Synthesis, Structure, and Study of Antibacterial and Antitumor Activity. <i>Inorganic Chemistry</i> , 2020, 59, 2978-2987.	1.9	15
146	Ein Organoruthenium-Tumorthapeutikum mit unerwartet hoher Selektivität für Plectin. <i>Angewandte Chemie</i> , 2017, 129, 8379-8383.	1.6	14
147	Nano-scale imaging of dual stable isotope labeled oxaliplatin in human colon cancer cells reveals the nucleolus as a putative node for therapeutic effect. <i>Nanoscale Advances</i> , 2021, 3, 249-262.	2.2	14
148	The influence of electroporation on cytotoxicity of anticancer ruthenium(III) complex KP1339 in vitro and in vivo. <i>Anticancer Research</i> , 2010, 30, 2055-63.	0.5	14
149	Functionalization of Ruthenium(II) (P^6 -p-cymene)(3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies. <i>ChemPlusChem</i> , 2017, 82, 841-847.	1.3	13
150	Antiproliferative Copper(II) and Platinum(II) Complexes with Bidentate N,N-Donor Ligands. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 3115-3124.	1.0	13
151	Morpho-metabotyping the oxidative stress response. <i>Scientific Reports</i> , 2021, 11, 15471.	1.6	13
152	Hydrolysis and Cytotoxic Properties of Osmium(II)/(III)-DMSO-Azole Complexes. <i>Short Communication. Chemistry and Biodiversity</i> , 2008, 5, 1588-1593.	1.0	12
153	Synthesis, structures and in vitro cytotoxicity of some cationic cis-platinum(II) complexes containing chelating thiocarbamates. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 462-466.	1.5	12
154	The rearrangement of tosylated flavones to 1 ϵ^2 -(alkylamino)aurones with primary amines. <i>Tetrahedron</i> , 2015, 71, 8953-8959.	1.0	12
155	Platinum(IV) Complexes Featuring Axial Michael Acceptor Ligands - Synthesis, Characterization, and Cytotoxicity. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 4049-4054.	1.0	12
156	Gallium and other main group metal compounds as antitumor agents. <i>Metal Ions in Biological Systems</i> , 2004, 42, 425-62.	0.4	12
157	Diamminetetrakis(carboxylato)platinum(IV) Complexes - Synthesis, Characterization, and Cytotoxicity. <i>Chemistry and Biodiversity</i> , 2012, 9, 1840-1848.	1.0	11
158	Amidoxime platinum(II) complexes: pH-dependent highly selective generation and cytotoxic activity. <i>New Journal of Chemistry</i> , 2017, 41, 6840-6848.	1.4	11
159	Comparative equilibrium and structural studies of new pentamethylcyclopentadienyl rhodium complexes bearing (O,N) donor bidentate ligands. <i>Journal of Organometallic Chemistry</i> , 2017, 846, 287-295.	0.8	10
160	Introducing N-, P-, and S-donor leaving groups: an investigation of the chemical and biological properties of ruthenium, rhodium and iridium thiopyridone piano stool complexes. <i>Dalton Transactions</i> , 2020, 49, 15693-15711.	1.6	10
161	Synthesis, Modification, and Biological Evaluation of a Library of Novel Water-Soluble Thiopyridone-Based Organometallic Complexes and Their Unexpected (Biological) Behavior. <i>Chemistry - A European Journal</i> , 2020, 26, 5419-5433.	1.7	10
162	Investigations on the Anticancer Potential of Benzothiazole-Based Metallacycles. <i>Frontiers in Chemistry</i> , 2020, 8, 209.	1.8	10

#	ARTICLE	IF	CITATIONS
163	Tridentate 3-Substituted Naphthoquinone Ruthenium Arene Complexes: Synthesis, Characterization, Aqueous Behavior, and Theoretical and Biological Studies. <i>Inorganic Chemistry</i> , 2021, 60, 9805-9819.	1.9	9
164	Multifunctional Pt(IV) prodrug candidates featuring the carboplatin core and deferoxamine. <i>Dalton Transactions</i> , 2021, 50, 8167-8178.	1.6	9
165	Synthesis and in vitro Antitumor Potency of (Cyclohexane-1,2-Diamine)Platinum(II) Complexes with Aminotris(Methylenephosphonic Acid) as Bone-Seeking Ligand. <i>Bioinorganic Chemistry and Applications</i> , 2005, 3, 179-190.	1.8	8
166	Osmium(II) Nitrosyl Complexes with Glycine, Picolinic Acid, L-Proline and D-Proline: Synthesis, Structures and Antiproliferative Activity. <i>Zeitschrift Fur Anorganische Und Allgemeine Chemie</i> , 2013, 639, 1590-1597.	0.6	8
167	The Impact of Leaving Group Variation on the Anticancer Activity of Molybdenocenes. <i>Organometallics</i> , 2018, 37, 3909-3916.	1.1	8
168	The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo? A Comparison of O,O-, S,O-, and N,N-Chelate Effects. <i>Chemistry - A European Journal</i> , 2020, 26, 2211-2221.	1.7	8
169	Novel phthiocol-based organometallics with tridentate coordination motif and their unexpected cytotoxic behaviour. <i>Dalton Transactions</i> , 2020, 49, 1393-1397.	1.6	8
170	The Effect of Cytoprotective Agents in Platinum Anticancer Therapy. , 2004, , 179-208.		8
171	Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent. <i>Dalton Transactions</i> , 2014, 43, 9851.	1.6	7
172	Bis- and Tetrakis(carboxylato)platinum(IV) Complexes with Mixed Axial Ligands – Synthesis, Characterization, and Cytotoxicity. <i>Chemistry and Biodiversity</i> , 2015, 12, 559-574.	1.0	7
173	Fine-Tuning the Activation Mode of an 1,3-Indandione-Based Ruthenium(II)-Cymene Half-Sandwich Complex by Variation of Its Leaving Group. <i>Molecules</i> , 2019, 24, 2373.	1.7	7
174	Bis- and Tris(carboxylato)platinum(IV) Complexes with Mixed Am(m)ine Ligands in the trans Position Exhibiting Exceptionally High Cytotoxicity. <i>European Journal of Inorganic Chemistry</i> , 2015, 2015, 1700-1708.	1.0	6
175	Synthesis, characterization, cytotoxic activity, and ¹⁹ F NMR spectroscopic investigations of (OC-6-33)-diacetato(ethane-1,2-diamine)bis(3,3,3-trifluoropropanoato)platinum(IV) and its platinum(II) counterpart. <i>Inorganica Chimica Acta</i> , 2019, 490, 190-199.	1.2	6
176	Naphthoquinones of natural origin: Aqueous chemistry and coordination to half-sandwich organometallic cations. <i>Journal of Organometallic Chemistry</i> , 2020, 907, 121070.	0.8	6
177	First insights into the novel class of organometallic compounds bearing a bidentate selenopyridone coordination motif: Synthesis, characterization, stability and biological investigations. <i>Inorganica Chimica Acta</i> , 2020, 513, 119919.	1.2	6
178	Systematic Study on the Cytotoxic Potency of Commonly Used Dimeric Metal Precursors in Human Cancer Cell Lines. <i>ChemistryOpen</i> , 2022, 11, e202200019.	0.9	6
179	Water-Soluble Cationic Derivatives of Indirubin, the Active Anticancer Component from <i>Indigo naturalis</i> . <i>Chemistry and Biodiversity</i> , 2012, 9, 2175-2185.	1.0	5
180	Design, synthesis, nuclear localization, and biological activity of a fluorescent duocarmycin analog, HxTfA. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1342-1347.	1.0	5

#	ARTICLE	IF	CITATIONS
181	Heart-cut 2DSEC-RP-LC-ICP-MS as a screening tool in metal-based anticancer research. <i>Journal of Analytical Atomic Spectrometry</i> , 2019, 34, 1279-1286.	1.6	5
182	Thermodynamic Genome-Scale Metabolic Modeling of Metallo drug Resistance in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4130.	1.7	5
183	Highly Aromatic Flavan-3-ol Derivatives from Palaeotropical <i>Artocarpus lacucha</i> Buch.-Ham Possess Radical Scavenging and Antiproliferative Properties. <i>Molecules</i> , 2021, 26, 1078.	1.7	4
184	Synthesis, Characterization, Cytotoxicity, and Time-Dependent NMR Spectroscopic Studies of (SP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Journal of Inorganic Chemistry</i> , 2019, 2019, 856-864.	1.0	3
185	Synthesis, characterization, lipophilicity and cytotoxic properties of novel bis(carboxylato)oxalatobis(1-propylamine)platinum(IV) complexes. <i>Inorganica Chimica Acta</i> , 2019, 491, 76-83.	1.2	3
186	KP772 overcomes multiple drug resistance in malignant lymphoma and leukemia cells in vitro by inducing Bcl-2-independent apoptosis and upregulation of Harakiri. <i>Journal of Biological Inorganic Chemistry</i> , 2021, 26, 897-907.	1.1	3
187	The effect of cytoprotective agents in platinum anticancer therapy. <i>Metal Ions in Biological Systems</i> , 2004, 42, 179-208.	0.4	2
188	Water-soluble trithiolato-bridged dinuclear ruthenium(II) and osmium(II) arene complexes with bisphosphonate functionalized ligands as anticancer organometallics. <i>Journal of Inorganic Biochemistry</i> , 2021, 225, 111618.	1.5	1
189	InnenrÃ¼cktitelbild: Ein Organorutheniumâ€Tumorthapeutikum mit unerwartet hoher SelektivitÃt fÃ¼r Plectin (<i>Angew. Chem.</i> 28/2017). <i>Angewandte Chemie</i> , 2017, 129, 8415-8415.	1.6	0